Hanmi Science Co (008930.KS) Stock Price
Hanmi Science Co Price
Revenue has compounded at 6.0% per year over the past 19 years to 1.36 T KRW. Earnings per share have grown at 2.6% per year over the last 19 years. Hanmi Science Co's net margin stands at 8.7%, up from 4.5% several years earlier. Hanmi Science Co currently offers a dividend yield of about 0.57%. The payout ratio is around 32% of earnings.
Hanmi Science Co stock price
Hanmi Science Co business model & stock analysis
Frequently asked questions about Hanmi Science Co
The business model of Hanmi Science Co Ltd., a South Korean company, revolves around its expertise in the field of biotechnology. Hanmi Science focuses on the development, manufacturing, and distribution of innovative pharmaceutical products. The company is committed to researching and creating cutting-edge drugs and therapies to address various medical conditions and improve patient outcomes. With a strong emphasis on research and development, Hanmi Science aims to enhance global healthcare by delivering novel treatment options to customers worldwide.
Hanmi Science Co Ltd is primarily active in the pharmaceutical and healthcare industries.
Hanmi Science Co Ltd faces competition from various companies in the market. Some of its main competitors include CJ Healthcare Corp, SK Biopharmaceuticals Co Ltd, and Yuhan Corporation. These competitors are also prominent players in the pharmaceutical and biotechnology industry.
Hanmi Science Co Ltd is a leading company in the healthcare industry. Established in 1973, Hanmi Science Co Ltd has a rich history of over four decades. The company focuses on research, development, and manufacturing of innovative medical devices and pharmaceutical products. With a strong commitment to improving global healthcare, Hanmi Science Co Ltd has made significant contributions to the industry. They have formed strategic partnerships and collaborations with renowned companies to enhance their capabilities and expand their global presence. Hanmi Science Co Ltd's dedication to quality, innovation, and customer satisfaction has positioned them as a trusted and reliable name in the healthcare sector.
Hanmi Science Co Ltd has achieved several significant milestones in its corporate history. The company made its debut in 1973 as a small chemical trading business and has since evolved into a leading global provider of pharmaceutical and healthcare solutions. Hanmi Science Co Ltd successfully developed and launched its first original drug, LUSEDRA, in 2008, marking a major advancement in the pharmaceutical sector. Additionally, the company has established numerous strategic partnerships and collaborations with global pharmaceutical giants, enabling it to enhance its research and development capabilities. Hanmi Science Co Ltd continues to foster innovation, expand its product pipeline, and deliver breakthrough treatments to improve patient outcomes.
Hanmi Science Co Ltd is primarily present in South Korea.
Hanmi Science Co Ltd represents values of innovation, excellence, and customer satisfaction. With a strong corporate philosophy focused on pioneering new technologies and providing top-notch services, Hanmi Science Co Ltd aims to meet the ever-evolving needs of its clients. By prioritizing research and development, the company strives to deliver cutting-edge solutions in the fields of biotechnology and pharmaceuticals. With a commitment to ethical practices, Hanmi Science Co Ltd also emphasizes integrity and social responsibility in its operations. Through its dedication to these values and its forward-thinking approach, Hanmi Science Co Ltd continues to make significant contributions to the industry.
Converted at the current exchange rate, the Hanmi Science Co share trades at 35.24 EUR (53,000.00 KRW).
The Hanmi Science Co share (008930.KS) is listed on 1 stock exchanges, including: KOSPI (Seoul) (008930.KS).
Hanmi Science Co Ltd is a leading company in the pharmaceutical industry that specializes in the research and development of innovative drugs and medical devices. The company offers a wide range of products and services divided into various business areas.
The revenue cannot currently be calculated for Hanmi Science Co.
The profit cannot currently be calculated for Hanmi Science Co.
The P/E ratio cannot be calculated for Hanmi Science Co at the moment.
The P/S cannot be calculated for Hanmi Science Co currently.
The Eulerpool Quality Score for Hanmi Science Co is 5/10.
The ISIN of Hanmi Science Co is KR7008930000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Hanmi Science Co is 008930.KS. The ticker symbol is used to trade Hanmi Science Co shares on the stock exchange.
Hanmi Science Co stock
Hanmi Science Co Peer Group
Hanmi Science Co Ticker
Hanmi Science Co FIGI
All fundamentals and in-depth analysis of Hanmi Science Co
Our stock analysis for Hanmi Science Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hanmi Science Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.